Исследование прокогнитивных эффектов высокоселективного антагониста 5НТ-6 рецепторов у больных шизофренией в состоянии ремиссии

1. Schaefer J., Giangrande E., Weinberger D.R., Dickinson D. The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr. Res. 2013 Oct;150(1):42-50. DOI: 10.1016/j.schres.2013.07.009

2. Mazure C.M., Nelson J.C., Jatlow P.I., Bowers M.B. Jr. Drug-responsive symptoms during early neuroleptic treat- ment. Psychiatry Res. 1992 Feb;41(2):147-154. DOI: http://dx.DOI.org/10.1016/0165-781(92)90106-D

3. Leucht S., Arbter D., Engel R.R., Kissling W., Davis J.M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry. 2009 Apr;14(4):429-447. DOI: 10.1038/sj.mp.4002136

4. Glennon R.A. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J. Med. Chem. 2003 Jul 3;46(14):2795- 2812. DOI: 10.1021/jm030030n

5. West P.J., Marcy V.R., Marino M.J., Schaffhauser H. Activa- tion of the 5-HT(6) receptor attenuateslong-term potenti- ation and facilitates GABAergic neurotransmission in rat hippocampus. Neuroscience. 2009 Dec 1;164(2):692-701. DOI: 10.1016/j.neuroscience.2009.07.061

6. de Foubert G., O'Neill M.J., Zetterström T.S. Acute onset by 5-HT(6)-receptor activation on rat brain brain-derived neurotrophic factor and activity-regulated cytoskeletal-as- sociated protein mRNA expression. Neuroscience. 2007 Jul 13;147(3):778-785. DOI: 10.1016/j.neuroscience.2007.04.045

7. Romero G., Sánchez E., Pujol M., Pérez P., Codony X., Ho- lenz J., Buschmann H., Pauwels P.J. Efficacy of selective 5-HT6 receptor ligands determined by monitoring 5-HT6 receptor-mediated cAMP signaling pathways. Br. J. Pharma- col. 2006 Aug; 148(8):1133-1143. Epub 2006 Jul 24. DOI: 10.1038/sj.bjp.0706827

8. Morozova M.A., Lepilkina T.A., Rupchev G.E., Beniashvi- ly A.G., Burminskiy D.S., Potanin S.S., Bondarenko E.V., Ka- zey V.I., Lavrovsky Y., Ivachtchenko A.V. Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study. CNS Spectr. 2014 Aug;19(4):316-323. DOI: 10.1017/S1092852913000394